Author Archive

CERS receives second PMA Approval. IMGN RHHBY release Phase 3 data + FATE SGYP TLOG updates

Dec 19, 2014 No Comments by

Latest updates to the Company Pipeline Database from December 18  2014. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Link Text Updated CERS 6.16 INTERCEPT Platelets Approved PMA approved Dec 18 2014 12/19/2014 FATE 3.7 ProHema Adult hematologic malignancies Phase 2 Phase 2 data due mid-2015. 12/19/2014 IMGN 10.85 Kadcyla […]

Daily News Read more

POZN issued CRL. Positive data for TTPH ASPX + updates for ARWR BIOD CARA CERU CERS CTIX CYCC GTHP ISIS OGXI RXII

Dec 18, 2014 No Comments by

Latest updates to the Company Pipeline Database from December 8 and 9 2014. Refer to the FDA Calendar for upcoming catalysts ARWR 6.09 ARC-520 injection in combination with entecavir or tenofovir Chronic HBV Phase 2b Announced December 16 that they intend to initiate Phase 2b trials to determine the depth of hepatitis B surface antigen (HBsAg) […]

Daily News Read more

Pipeline updates for ACOR BLRX EXEL RARE SPHS LPCN VBLT ZFGN

Dec 16, 2014 No Comments by

Latest updates to the Company Pipeline Database from December 15 2014. Refer to the FDA Calendar for upcoming catalysts Ticker Price Drug Indication Stage Link Text Updated ACOR 38.4 Dalfampridine Post stroke deficits Phase 2b/3 Annonuced Dec 15, 2015 that a Phase 3 trial has been initiated 12/16/2014 BLRX 1.63 BL-8040 Cancer – Acute myeloid leukemia […]

Daily News Read more

CCXI topline CCX140 data due Fri + updates for FOLD BLUE KPTI VICL NKTR

Dec 12, 2014 No Comments

Latest updates to the Company Pipeline Database from December 11 2014. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Link Text Updated BLUE  86.12 LentiGlobin – HGB-206 Sickle disease Phase 1/2 Most likely to have initial data 1H 2015, as per JPM estimate 12/12/2014 CCXI 4.49 CCX140 Diabetic nephropathy Phase […]

Read more

ACOR initiates Phase 3 Parkinson’s trial. NBIX initiates Phase 1/2 trial of NBI-77860 + BMRN update

Dec 11, 2014 No Comments

Latest updates to the Company Pipeline Database from December 10 2014. Refer to the FDA Calendar for upcoming catalysts Ticker Price Drug Indication Stage Link Text Updated ACOR  38.29 CVT-301 OFF episodes of Parkinson’s disease (PD) Phase 3 Announced Dec 10 that enrolment in their Phase 3 trial has been initiated for the treatment of OFF […]

Read more

Updates for BDSI BLUE DVAX INCY MEIP TGTX IRWD

Dec 10, 2014 1 Comment

Latest updates to the Company Pipeline Database from December 8 and 9 2014. Refer to the FDA Calendar for upcoming catalysts Ticker Price Drug Indication Stage Link Text Updated BDSI 15.05 Clonidine gel Painful diabetic neuropathy (PDN) Phase 3 Announced that they have completed the randomization of all patients, with Phase 3 topline data due by the […]

Read more

INCY FDA Approval + Updates for ADMA APRI CLDX EARS NERV

Dec 05, 2014 No Comments

Latest updates to the Company Pipeline Database from December 3 and 4 2014. Refer to the FDA Calendar for upcoming catalysts Ticker Price Drug Indication Stage Link Text Updated ADMA 10.80 RI-002 Primary Immune Deficiency Diseases Phase 3 Phase 3 prelim data released December 2014 met endpoint. Final data due 1Q 2015. BLA filing planned for […]

Read more

PBYI NDA filing delay + updates for AERI GEVA GWPH PRTA LPCN

Dec 03, 2014 No Comments

December 2 catalyst updates: AERI 28.51 Rhopressa Glaucoma Phase 3 Phase 3 Rocket 1 trial completed enrolment Dec 2014. Data due mid-2015 12/3/2014 GEVA 81.78 Sebelipase alfa (SBC-102) Late onset lysosomal acid lipase deficiency (LAL Deficiency) BLA BLA rolling submission completed Dec 2014 12/3/2014 GWPH 68.66 Epidiolex Lennox-Gastaut syndrome (LGS) Phase 3 Phase 3 to […]

Read more

EXEL fails Phase 3 COMET-2 trial + updates for CANF FLXN GLMD QURE NKTR

Dec 02, 2014 No Comments

Latest updates to the Company Pipeline Database from December 1 2014: Ticker Price Drug Indication Stage Notes Updated CANF 4.45 CF101 Psoriasis Phase 2/3 Phase 2/3 topline data due 1Q 2015 12/2/2014 CANF 4.45 CF101 Rheumatoid arthritis Phase 3 Phase 3 planned 12/2/2014 CANF 4.45 CF101 Glaucoma Phase 2 Phase 2 data due 2Q or […]

Read more

FDA Calendar updated + change in news format

Nov 27, 2014 2 Comments

BioPharmCatalyst is pleased to let readers know that the FDA Calendar has been fully updated following the recent publication of 3Q financial results. BioPharmCatalyst will also be trialing a new format to inform readers of the latest changes to the website. Instead of providing a daily summary of day’s news, readers will be provided with […]

Read more

Upcoming data for CUR KBIO NKTR. AVNR approval delay likely. DVAX reverse split + AEZS RMTI GNCA HRTX IMMU TLOG OPK DSCO ANAC IMMU HPTX SPPI RPTP CMRX VSAR

Nov 08, 2014 No Comments

Neuralstem, Inc. (NYSE MKT: CUR) announced that the Phase 2 data lock of NSI-566 spinal cord-derived stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS) is scheduled to conclude in late January 2015 at which time the company anticipates providing its Phase 2 ALS results. The company also noted that a Phase 2 trial of NSI-189 for […]

Read more